![Jeffrey Almond](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffrey Almond
Direktor/Vorstandsmitglied bei iosBio Ltd.
Profil
Jeffrey Almond is a Non-Executive Director at iosBio Ltd.
He was previously the Chairman at Virion Biotherapeutics Ltd., Director at The Medical Research Council, Principal at The University of Reading, and Vice President-Discovery Research at Sanofi Pasteur Holding SA.
Aktive Positionen von Jeffrey Almond
Unternehmen | Position | Beginn |
---|---|---|
iosBio Ltd.
![]() iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jeffrey Almond
Unternehmen | Position | Ende |
---|---|---|
Virion Biotherapeutics Ltd.
![]() Virion Biotherapeutics Ltd. BiotechnologyHealth Technology Virion Biotherapeutics Ltd. operates as a biotechnology company that develops novel therapeutics for respiratory viral infections. The firm focuses on prevention and treatment of influenza and respiratory syncytial virus. The company was founded by Nigel Dimmock and Andrew Easton in 2017 and is headquartered in Coventry, the United Kingdom. | Vorsitzender | - |
Sanofi Pasteur Holding SA
![]() Sanofi Pasteur Holding SA BiotechnologyHealth Technology Sanofi Pasteur Holding SA develops and manufactures vaccines. The company is headquartered in Antony, France. | Technik-/Wissenschafts-/F&E-Leiter | - |
The University of Reading | Corporate Officer/Principal | - |
The Medical Research Council
![]() The Medical Research Council Miscellaneous Commercial ServicesCommercial Services The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
The Medical Research Council
![]() The Medical Research Council Miscellaneous Commercial ServicesCommercial Services The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom. | Commercial Services |
Sanofi Pasteur Holding SA
![]() Sanofi Pasteur Holding SA BiotechnologyHealth Technology Sanofi Pasteur Holding SA develops and manufactures vaccines. The company is headquartered in Antony, France. | Health Technology |
iosBio Ltd.
![]() iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | Technology Services |
Virion Biotherapeutics Ltd.
![]() Virion Biotherapeutics Ltd. BiotechnologyHealth Technology Virion Biotherapeutics Ltd. operates as a biotechnology company that develops novel therapeutics for respiratory viral infections. The firm focuses on prevention and treatment of influenza and respiratory syncytial virus. The company was founded by Nigel Dimmock and Andrew Easton in 2017 and is headquartered in Coventry, the United Kingdom. | Health Technology |